DRD1, DRD2: Dopamine D1 and D2 receptor
Selectivity group in Homo sapiens that 2 drugs act on.
- Drugs that act on it: 2
- Approved: 2
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on DRD1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
| MinaprineWithdrawn | Approved | AstraZeneca Pharmaceuticals | Small molecule | AgonistDopamine D1 and D2 receptor agonist | 1 |
| AmineptineWithdrawn | Approved | — | Small molecule | AntagonistDopamine D1 and D2 receptor antagonist | 0 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Minaprine | Phase 2 | Active, not recruiting | AstraZeneca | Jan 27, 2025 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2111341, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets